NASDAQ:ARCT
Arcturus Therapeutics Holdings Inc. Stock News
$27.27
+0.750 (+2.83%)
At Close: May 03, 2024
Why Is Everyone Talking About Arcturus Therapeutics Stock?
07:27am, Tuesday, 05'th Jan 2021
This clinical-stage biotech has been a wild ride for investors, and the shifting outlook for its COVID-19 vaccine candidate is the reason why.
Arcturus gets FDA go-ahead to begin Phase 2 trial for COVID-19 vaccine candidate
07:22am, Monday, 04'th Jan 2021
Shares of Arcturus Therapeutics Holdings Inc. gained 3.7% in premarket trading on Monday after the company said the Food and Drug Administration will allow it to move forward with a Phase 2 clinical t
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States
Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis
09:47am, Thursday, 31'st Dec 2020
Arcturus (ARCT) has selected ARCT-032 as a development candidate for Cystic Fibrosis.
These Were the 5 Top Genetics Stocks of 2020
06:26am, Thursday, 31'st Dec 2020
Investors in fast-moving biotechs made out like bandits.
Arcturus' (ARCT) Shares Fall on COVID-19 Vaccine Study Results
12:02pm, Wednesday, 30'th Dec 2020
Arcturus (ARCT) releases not so encouraging data from its phase I/II and preclinical study on its coronavirus vaccine candidate, ARCT-021.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #CFTR--Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease
Markets Ease Lower as Arcturus, Blink Charging Plunge
05:35pm, Tuesday, 29'th Dec 2020
Two top performers fell back to earth on Tuesday.
Arcturus Reports Results From Early-Stage Testing of Its Coronavirus Vaccine
04:33pm, Tuesday, 29'th Dec 2020
Investors obviously considered these to be underwhelming, however.
Arcturus Therapeutics plummets 53% after analyst downgrades following COVID-19 vaccine trial updates (ARCT)
01:32pm, Tuesday, 29'th Dec 2020
Arcturus Therapeutics fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical company's COVID-19 vaccine updates. Arct
Why Arcturus Therapeutics Stock Is Plunging Today
11:42am, Tuesday, 29'th Dec 2020
The biotech announced disappointing early stage results for its single-dose COVID-19 vaccine candidate.
Why Analysts Lost Confidence in the Arcturus COVID-19 Vaccine
11:27am, Tuesday, 29'th Dec 2020
An update on its COVID-19 vaccine candidate sent Arcturus Therapeutics Holdings Inc.
Why Shares Of Coronavirus Vaccine Developer Arcturus Are Sinking
10:47am, Tuesday, 29'th Dec 2020
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shares were retreating sharply Tuesday after the company issued an update on its coronavirus vaccine program. What Happened: San Diego, California-b
Arcturus Therapeutics shares slide 37% in premarket after COVID vaccine data are deemed ‘underwhelming'
08:57am, Tuesday, 29'th Dec 2020
Investors respond to results from a Phase 1/2 trial of its COVID-19 vaccine candidate that one analyst said were disappointing.
Lemonade Stock Gains, Arcturus Therapeutics Tumbles as Market Rally Continues
08:55am, Tuesday, 29'th Dec 2020
The Dow Jones Industrial Average was on the rise Tuesday after House Democrats passed a version of the fiscal stimulus bill that includes larger payments to households.
